Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancer
Shinya Ohara(Hiroshima University), Wataru Yasui(Hiroshima University)
Cited by 52
Related Papers
KIFC1 Inhibitor CW069 Induces Apoptosis and Reverses Resistance to Docetaxel in Prostate Cancer
|Journal of Clinical Medicine|2019|55